Please login to the form below

Not currently logged in
Email:
Password:

Idera Pharmaceuticals names new CEO

Vincent Milano was most recently CEO of Viropharma

Vincent Milano has been appointed CEO of Idera Pharmaceuticals almost one year after stepping down as CEO of ViroPharma.

Milano left rare disease specialist ViroPharma in January 2014 shortly after the company was acquired by Shire Pharmaceuticals.

He now takes charge of Idera, a clinical-stage biopharmaceutical company that also has an interest in rare diseases.

Jim Geraghty, chairman of Idera, commented on Milano's success at ViroPharma: “Vin is an experienced biopharmaceutical executive with a proven track record of value creation, who led ViroPharma to become a widely admired company successfully delivering innovative treatments to patients with serious unmet medical needs."

Milano succeeds Sudhir Agrawal, who will remain at Idera as president of research and will serve on the company's board of directors.

“As a co-founding scientist and a pioneer in the field of nucleic acid therapeutics, he will continue to lead scientific research for the company,” said Geraghty.

Milano spent nearly 20 years at ViroPharma serving as chief financial officer from 1997 to 2006 when he was named CEO. His previous experience includes a senior manager role at accounting firm KPMG.

5th December 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics